SK Biopharmaceuticals Co., Ltd. (326030.KS)

KRW 103600.0

(-2.54%)

Total Liabilities Summary of SK Biopharmaceuticals Co., Ltd.

SK Biopharmaceuticals Co., Ltd.'s latest annual total liabilities in 2023 was 402.21 Billion KRW , up 15.69% from previous year.
SK Biopharmaceuticals Co., Ltd.'s latest quarterly total liabilities in 2024 Q2 was 452.56 Billion KRW , up 0.25% from previous quarter.
SK Biopharmaceuticals Co., Ltd. reported annual total liabilities of 347.68 Billion KRW in 2022, up 74.31% from previous year.
SK Biopharmaceuticals Co., Ltd. reported annual total liabilities of 199.46 Billion KRW in 2021, up 64.61% from previous year.
SK Biopharmaceuticals Co., Ltd. reported quarterly total liabilities of 451.42 Billion KRW for 2024 Q1, up 12.23% from previous quarter.
SK Biopharmaceuticals Co., Ltd. reported quarterly total liabilities of 339.77 Billion KRW for 2023 Q1, down -2.27% from previous quarter.

Annual Total Liabilities Chart of SK Biopharmaceuticals Co., Ltd. (2023 - 2011)

Historical Annual Total Liabilities of SK Biopharmaceuticals Co., Ltd. (2023 - 2011)

Year	Total Liabilities	Total Liabilities Growth
2023	402.21 Billion KRW	15.69%
2022	347.68 Billion KRW	74.31%
2021	199.46 Billion KRW	64.61%
2020	121.17 Billion KRW	-20.33%
2019	152.09 Billion KRW	312.12%
2018	36.9 Billion KRW	-27.81%
2017	51.12 Billion KRW	10.64%
2016	46.2 Billion KRW	62.59%
2015	28.41 Billion KRW	26.75%
2014	22.42 Billion KRW	6.79%
2013	20.99 Billion KRW	-7.72%
2012	22.75 Billion KRW	43.96%
2011	15.8 Billion KRW	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q2	452.56 Billion KRW	0.25%
2024 Q1	451.42 Billion KRW	12.23%
2023 Q1	339.77 Billion KRW	-2.27%
2023 Q2	339.42 Billion KRW	-0.1%
2023 Q3	428.56 Billion KRW	26.26%
2023 Q4	402.21 Billion KRW	-6.15%
2023 FY	402.21 Billion KRW	15.69%
2022 Q2	232.52 Billion KRW	11.06%
2022 FY	347.68 Billion KRW	74.31%
2022 Q4	347.68 Billion KRW	0.06%
2022 Q3	347.48 Billion KRW	49.44%
2022 Q1	209.37 Billion KRW	4.97%
2021 FY	199.46 Billion KRW	64.61%
2021 Q3	127.26 Billion KRW	-5.42%
2021 Q2	134.55 Billion KRW	16.4%
2021 Q1	115.6 Billion KRW	-4.6%
2021 Q4	199.46 Billion KRW	56.74%
2020 FY	121.17 Billion KRW	-20.33%
2020 Q2	257.92 Billion KRW	-2.72%
2020 Q4	121.17 Billion KRW	2.66%
2020 Q3	118.03 Billion KRW	-54.24%
2020 Q1	265.13 Billion KRW	74.32%
2019 Q4	152.09 Billion KRW	0.0%
2019 FY	152.09 Billion KRW	312.12%
2018 FY	36.9 Billion KRW	-27.81%
2017 FY	51.12 Billion KRW	10.64%
2016 FY	46.2 Billion KRW	62.59%
2015 FY	28.41 Billion KRW	26.75%
2014 FY	22.42 Billion KRW	6.79%
2013 FY	20.99 Billion KRW	-7.72%
2012 FY	22.75 Billion KRW	43.96%
2011 FY	15.8 Billion KRW	0.0%

Peer Total Liabilities Comparison of SK Biopharmaceuticals Co., Ltd.

Name	Total Liabilities	Total Liabilities Difference
ORIENT BIO Inc.	11.89 Billion KRW	-3282.323%
Green Cross Holdings Corporation	1856.16 Billion KRW	78.331%
Green Cross Holdings Corporation	1103.45 Billion KRW	63.549%
Pharmicell Co., Ltd.	18.79 Billion KRW	-2040.109%
Green Cross Corporation	1103.45 Billion KRW	63.549%
GeneOne Life Science, Inc.	39.51 Billion KRW	-917.8%
Celltrion, Inc.	2791.73 Billion KRW	85.593%
Samsung Biologics Co.,Ltd.	6215.7 Billion KRW	93.529%
SK bioscience Co.,Ltd.	148.58 Billion KRW	-170.702%
Prestige BioPharma Limited	196.21 Billion KRW	-104.985%